EUCTR2016-004822-41-FI进行中（未招募）1 期
An open-label, parallel-group, randomized, multicenter study to assess the safety and efficacy of vilaprisan in subjects with uterine fibroids versus standard of care - ASTEROID 6: Assess safety and efficacy of BAY1002670 in subjects with uterine fibroids
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- Bayer AG
- 入组人数
- 1,302
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •1. Signed and dated informed consent
- •2. 18 years or older
- •3.Diagnosis of uterine fibroid(s) documented by ultrasound at screening AND/OR during a uterine preserving procedure within 3 months prior to screening in subjects with high risk for recurrence
- •4. At least one symptom of uterine fibroid(s) - bleeding, pelvic pressure/pain
- •5. Good general health
- •6. Normal or clinically insignificant cervical smear
- •7. An endometrial biopsy performed during the screening period, without significant histological disorder
- •8.Use of an acceptable nonhormonal method of contraception starting at Visit 1 until the end of the study
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 1302
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Pregnancy or lactation (less than 3 months since delivery, abortion, or lactation before start of treatment)
- •2. Hypersensitivity to any ingredient of the study drug
- •3. Any condition requiring immediate blood transfusion
- •4. Any diseases, conditions, or medications that can compromise the function of the body systems and could result in altered absorption, excessive accumulation, impaired metabolism, or altered excretion of the study drug
- •5. Any diseases or conditions that might interfere with the conduct of the study or the interpretation of the results
- •6. Abuse of alcohol, drugs, or medicines (eg, laxatives)
- •7. Use of other treatments that might interfere with the conduct of the study or the interpretation of the results
- •8. Undiagnosed abnormal genital bleeding
研究者
相似试验
进行中（未招募）
1 期
Assess safety and efficacy of vilaprisan in subjects with uterine fibroidsEUCTR2016-004822-41-CZBayer AG1,302
进行中（未招募）
1 期
Assess safety and efficacy of vilaprisan in subjects with uterine fibroidsWomen, 18 years or older, diagnosis of uterine fibroid(s) documented by ultrasound at screening and/or during a uterine preserving procedure within 3 months prior to screening in subjects with high risk for recurrence, at least one symptom of uterine fibroid(s) - bleeding, pelvic pressure/pain, good general health, normal or clinically insignificant cervical smear and an endometrial biopsy performed during the screening period without significant histologic disorderMedDRA version: 21.1Level: LLTClassification code 10016628Term: FibroidsSystem Organ Class: 100000004864EUCTR2016-004822-41-PLBayer AG1,302
进行中（未招募）
1 期
Multicenter clinical trial comparing the efficacy and safety of two strategies in the prevention of cytomegalovirus infection in kidney transplant recipients.Prophylaxis of cytomegalovirus infection in seropositive kidney transplant recipients.EUCTR2011-005708-13-ESFundación para la Investigación Biomedica del Hospital 12 de Octubre
进行中（未招募）
1 期
Evaluation of efficacy and safety of DCVAC/OvCa (therapeutic ovarian cancer vaccine) in women with relapsed platinum sensitive ovarian carcinomaepithelial ovarian carcinomaMedDRA version: 18.0Level: PTClassification code 10061328Term: Ovarian epithelial cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2013-001323-38-DESOTIO a.s.60
进行中（未招募）
1 期
Evaluation and efficacy and safety of DCVAC/OvCa (therapeutic ovarian cancer vaccine) in woman with relapsed platinum resistant epithelial ovarian carcinomaepithelial ovarian carcinomaMedDRA version: 16.0Level: PTClassification code 10061328Term: Ovarian epithelial cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2013-001325-24-CZSOTIO a.s.60